Effect of Vericiguat on Cardiac-Renal Function and Prognosis in Elderly Patients with Heart Failure
SUN Guijia
KONG Haibo
CHENG Hongjuan
TONG Sen
ZHANG Xiaomin
FENG Qiang
LI Hui
Abstract：Objective To explore the efficacy of vericiguat and its influence on cardiac and renal function and prognosis in elderly patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 104 elderly patients with HFrEF admitted to the Cardiology Department of Handan Central Hospital between November 2022 and January 2024 were selected and randomly divided into a conventional treatment group(n=52,receiving conventional therapy)and a vericiguat-combined group(n=52,receiving conventional therapy combined with vericiguat)according to the random number table method.After 6 months of treatment,the efficacy,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),plasma N-terminal pro-B-type natriuretic peptide(NT-proBNP),6-minute walk test(6MWT),blood urea nitrogen(BUN),and serum creatinine(SCr)before and after treatment were compared between the two groups.The occurrence of major adverse cardiovascular event(MACE)within 6 months was also observed.Results After treatment,the total effective rate in the vericiguat-combined group was 98.08%,which was higher than that in the conventional treatment group(84.62%,P<0.05).After treatment,LVEF[(59.28±5.24)%]and 6MWT[(447.92±72.75)m]in the vericiguat-combined group were significantly higher than those in the conventional treatment group[(51.87±4.37)%and(407.21±70.12)m,respectively],while LVEDD[(55.47±4.13)mm],LVESD[(34.19±3.24)mm],and NT-proBNP level[(361.24±28.26)pg/mL]in the vericiguat-combined group were significantly lower than those in the conventional treatment group[(64.91±5.84)mm,(38.52±3.71)mm,and(394.31±30.36)pg/mL,respectively],with statistically significant differences(P<0.001).Before and after treatment,there were no statistically significant differences in BUN and Scr levels between the two groups(P>0.05).The proportions of all-cause mortality,heart failure rehospitalization,myocardial infarction,and malignant arrhythmia in the vericiguat-combined group were all lower than those in the conventional treatment group(P<0.05).Conclusion Vericiguat has a definite curative effect in the treatment of HFrEF,can effectively improve cardiac function without negative effects on renal function,reduces the incidence of MACE,and improves prognosis.
Keywords：vericiguatheart failure with reduced ejection fractionefficacycardiac functionrenal functionprognosis
Publication Date：2026-01-20
Online Publishing Date：2026-01-24(First online date of this platform, not the publication date of the document)
Pages：5( 165-169 )